|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||465.489 g/mol g·mol−1|
|3D model (JSmol)|
|Melting point||228.65 °C (443.57 °F)|
|Boiling point||587.2 °C (1,089.0 °F)|
|Solubility in water||0.0015 mg/mL (20 °C)|
Omiloxetine (omiloextinum, omiloxetino INN):212-213 was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.
- WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
- Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
- De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|